Dual Antiplatelet Therapy: Guidance for Nurse Practitioners

Amsterdam, 2014, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines, J Am Coll Cardiol, 64, e139, 10.1016/j.jacc.2014.09.017 O’Gara, 2013, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, J Am Coll Cardiol, 61, e78, 10.1016/j.jacc.2012.11.019 Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, Circulation, 124, 2458, 10.1161/CIR.0b013e318235eb4d Levine, 2016, 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease, Circulation, 134, e123, 10.1161/CIR.0000000000000404 Rapsomaniki, 2016, Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction, Eur Heart J Qual Care Clin Outcomes, 2, 172, 10.1093/ehjqcco/qcw004 Virani, 2020, Heart disease and stroke statistics-2020 update: a report from the American Heart Association, Circulation, 141, e139, 10.1161/CIR.0000000000000757 Halkar, 2016, Dual antiplatelet therapy for acute coronary syndromes: how long to continue?, Cleve Clin J Med, 83, 675, 10.3949/ccjm.83a.15092 Gurbel, 2016, Platelet-mediated thrombosis: from bench to bedside, Circ Res, 118, 1380, 10.1161/CIRCRESAHA.115.307016 Al-Najjar, 2021, P2Y12 antagonists: approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies, Eur J Med Chem, 227, 113924, 10.1016/j.ejmech.2021.113924 Raber, 2019, The rise and fall of aspirin in the primary prevention of cardiovascular disease, Lancet, 393, 2155, 10.1016/S0140-6736(19)30541-0 Schoener, 2017, Reversal of the platelet inhibitory effect of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issue, Clin Res Cardiol, 106, 868, 10.1007/s00392-017-1128-8 Floyd, 2017, Indications for anticoagulant and antiplatelet combined therapy, BMJ, 359, j3782, 10.1136/bmj.j3782 Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746 Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482 Lilly Medical Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327 Sanofi-Aventis Garg, 2015, Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents, Am Heart J, 169, 222, 10.1016/j.ahj.2014.11.002 Bhatt, 2007, Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial, J Am Coll Cardiol, 49, 1982, 10.1016/j.jacc.2007.03.025 Mauri, 2014, Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents, N Engl J Med, 371, 2155, 10.1056/NEJMoa1409312 Bonaca, 2017, Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54, J Am Coll Cardiol, 70, 1368, 10.1016/j.jacc.2017.07.768 Magnani, 2021, Predictors, type, and impact of bleeding on the net clinical benefit of long-term ticagrelor in stable patients with prior myocardial infarction, J Am Heart Assoc, 10 Urban, 2019, Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk, Circulation, 140, 240, 10.1161/CIRCULATIONAHA.119.040167 Costa, 2017, Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials, Lancet, 389, 1025, 10.1016/S0140-6736(17)30397-5 Yeh, 2016, Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention, JAMA, 315, 1735, 10.1001/jama.2016.3775 Angiolillo, 2017, International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies, Circulation, 136, 1955, 10.1161/CIRCULATIONAHA.117.031164 Khan, 2021, De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies, Eur Heart J Cardiovasc Pharmacother, 7, 209, 10.1093/ehjcvp/pvaa025 Kim, 2020, Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial, JAMA, 323, 2407, 10.1001/jama.2020.7580 Mehran, 2019, Ticagrelor with or without aspirin in high-risk patients after PCI, N Engl J Med, 381, 2032, 10.1056/NEJMoa1908419 Schoos, 2019, Patterns and impact of dual antiplatelet cessation on cardiovascular risk after percutaneous coronary intervention in patients with acute coronary syndromes, Am J Cardiol, 123, 709, 10.1016/j.amjcard.2018.11.051 Bonaca, 2016, Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial, JAMA Cardiol, 1, 425, 10.1001/jamacardio.2016.1017 Biscaglia, 2017, A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: a randomized controlled trial, PLoS One, 12, 10.1371/journal.pone.0182124 Raposeiras-Roubin, 2020, Usefulness of bleeding after acute coronary syndromes for unmasking silent cancer, Am J Cardiol, 125, 1801, 10.1016/j.amjcard.2020.03.023 Guo, 2021, Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis, Front Pharmacol, 12 Banerjee, 2017, Use of antiplatelet therapy/DAPT for post-PCI patients undergoing noncardiac surgery, J Am Coll Cardiol, 69, 1861, 10.1016/j.jacc.2017.02.012 Valgimigli, 2018, Eur Heart J, 39, 213, 10.1093/eurheartj/ehx419